RxSight (RXST) Aperçu de l'action
RxSight, Inc. est une société de technologie médicale au stade commercial qui se consacre à la recherche et au développement, à la fabrication et à la vente de lentilles intraoculaires ajustables à la lumière (LAL) utilisées dans la chirurgie de la cataracte aux États-Unis. Plus de détails
| Score flocon de neige | |
|---|---|
| Évaluation | 3/6 |
| Croissance future | 0/6 |
| Performances passées | 0/6 |
| Santé financière | 6/6 |
| Dividendes | 0/6 |
RXST Community Fair Values
Create NarrativeSee what 14 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
US$50
FV
87.8% sous-évalué décote intrinsèque127
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
RxSight, Inc. Concurrents
Historique des prix et performances
| Historique des cours de bourse | |
|---|---|
| Prix actuel de l'action | US$6.09 |
| Plus haut sur 52 semaines | US$16.48 |
| Plus bas sur 52 semaines | US$5.30 |
| Bêta | 1.23 |
| Variation sur 1 mois | -16.07% |
| Variation sur 3 mois | -30.93% |
| Variation sur 1 an | -61.99% |
| Variation sur 3 ans | -75.81% |
| Variation sur 5 ans | n/a |
| Évolution depuis l'introduction en bourse | -61.97% |
Nouvelles et mises à jour récentes
Mise à jour du récit • May 03
RXST: Future Returns Will Rely On 2026 Revenue Guidance Reset
Analyst price targets on RxSight have been reset in a tight range around $9 to $10, as analysts adjust models following Q4 results and the company's 2026 revenue outlook. Analyst Commentary Bullish Takeaways Bullish analysts see the updated 2026 revenue outlook of US$120m to US$135m as providing a clearer foundation for modeling, which helps support price targets clustered in the US$9 to US$10 range.Mise à jour du récit • Apr 18
RXST: Future Returns Will Rely On Reset 2026 Revenue Guidance
Analysts have trimmed RxSight's fair value estimate from about $10.21 to $9.93, reflecting recent price target adjustments after Q4 results and updated 2026 revenue guidance. Analyst Commentary Recent Street research around RxSight centers on updated price targets and the new 2026 revenue outlook, with opinions clustering around a more cautious but still engaged stance.Mise à jour du récit • Apr 04
RXST: Future Returns Will Rely On New CFO And 2026 Revenue Guidance
Analysts now see RxSight's fair value edging up to about $10.21 per share from roughly $10.06, reflecting recent price target moves clustered around $9 to $10 as they incorporate updated 2026 guidance, Q4 results and leadership changes into their models. Analyst Commentary Recent research paints a mixed picture around RxSight, with price targets clustered around the high single digits and ratings generally sitting in the middle of the scale.Recent updates
Mise à jour du récit • May 03
RXST: Future Returns Will Rely On 2026 Revenue Guidance Reset
Analyst price targets on RxSight have been reset in a tight range around $9 to $10, as analysts adjust models following Q4 results and the company's 2026 revenue outlook. Analyst Commentary Bullish Takeaways Bullish analysts see the updated 2026 revenue outlook of US$120m to US$135m as providing a clearer foundation for modeling, which helps support price targets clustered in the US$9 to US$10 range.Mise à jour du récit • Apr 18
RXST: Future Returns Will Rely On Reset 2026 Revenue Guidance
Analysts have trimmed RxSight's fair value estimate from about $10.21 to $9.93, reflecting recent price target adjustments after Q4 results and updated 2026 revenue guidance. Analyst Commentary Recent Street research around RxSight centers on updated price targets and the new 2026 revenue outlook, with opinions clustering around a more cautious but still engaged stance.Mise à jour du récit • Apr 04
RXST: Future Returns Will Rely On New CFO And 2026 Revenue Guidance
Analysts now see RxSight's fair value edging up to about $10.21 per share from roughly $10.06, reflecting recent price target moves clustered around $9 to $10 as they incorporate updated 2026 guidance, Q4 results and leadership changes into their models. Analyst Commentary Recent research paints a mixed picture around RxSight, with price targets clustered around the high single digits and ratings generally sitting in the middle of the scale.Mise à jour du récit • Mar 20
RXST: Future Returns Will Hinge On New CFO And 2026 Guidance
RxSight's updated fair value estimate has edged slightly lower, in line with Street price targets drifting from around $10 to a range centered near $9 to $10, as analysts factor in refreshed models, 2026 revenue guidance of $120M to $135M, and a mix of target cuts and raises that still cluster around neutral ratings. Analyst Commentary Recent research keeps RxSight broadly in neutral territory, with modest target changes reflecting updated revenue models, the new 2026 guidance range of $120M to $135M, and reactions to management changes.Mise à jour du récit • Mar 06
RXST: Future Returns Will Hinge On New CFO And Execution Quality
Analysts have nudged their blended price target on RxSight lower to about $10.17 from $10.39, reflecting updated views on revenue growth, margins, and future P/E after recent neutral ratings and mixed target moves in the $9 to $10 range. Analyst Commentary Recent research paints a mixed picture for RxSight, with most firms holding neutral ratings and fine tuning their targets in a relatively tight range around the current blended estimate.
Nouveau récit • Feb 25
Is This Lens Maker Mispriced? A Blind Spot in Plain Sight
RxSight (NASDAQ: RXST), maker of the only cataract lens that can be adjusted post-surgery, could be undervalued by an eye-popping margin More than 70% of RxSight Light Adjustable Lens (LAL) patients reported 20/20 or better vision after receiving the lens. Only 36.3% of non-adjustable lens patients reported the same.Mise à jour du récit • Feb 18
RXST: Future Returns Will Depend On New CFO And Execution Quality
Analysts have raised their average price target on RxSight by $1, citing the recent Piper Sandler move, a neutral initiation that adds coverage breadth, and supportive commentary around the new CFO appointment as reasons for a slightly refined outlook on growth, profitability, and future P/E expectations. Analyst Commentary Recent Street research on RxSight centers on how the new CFO, updated guidance commentary, and modest target changes feed into expectations for execution quality and valuation support.Mise à jour du récit • Feb 03
RXST: Future Returns Will Hinge On New CFO And Execution Confidence
Analysts have nudged their price targets on RxSight modestly higher, with updated models pointing to slightly stronger revenue growth and profit margins and a marginally lower discount rate, while some recent research highlights a move to a $10 target and views the new CFO appointment as supportive of the story. Analyst Commentary Recent research on RxSight reflects a mix of cautious optimism and lingering questions around execution, valuation and the setup after recent share price moves.Mise à jour du récit • Jan 20
RXST: Future Returns Will Depend On Comfortable Revenue And New CFO Execution
Analysts nudged their fair value estimate for RxSight slightly higher to about $10.39 from $10.33, citing better than anticipated recent quarters, a new CFO appointment they view positively, and Street research highlighting revenue that came in ahead of prior expectations, with longer term revenue forecasts described as comfortable. Analyst Commentary Recent Street research paints a mixed but generally constructive picture around RxSight, with attention on execution in recent quarters, the new CFO appointment, and how current revenue trends line up with existing expectations.Article d’analyse • Jan 10
We're Hopeful That RxSight (NASDAQ:RXST) Will Use Its Cash Wisely
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...Mise à jour du récit • Jan 05
RXST: Future Returns Will Hinge On Sustaining Comfortable Revenue Expectations
Analysts lifted their fair value estimate for RxSight to about $10.33 from $9.89 after a recent price target increase to $10.00. They pointed to a quarter they viewed as better than feared, with revenue of $30m above prior estimates and current Street revenue expectations that they describe as comfortable.Mise à jour du récit • Dec 13
RXST: Future Returns Will Depend On Sustaining Recent Revenue Outperformance
Analysts modestly raised their price target on RxSight to $10 from $8, citing a quarter that exceeded revenue expectations and growing confidence that current Street forecasts for 2026 sales are achievable. Analyst Commentary Analysts are digesting the stronger than expected quarter and reassessing the balance between upside potential and execution risks for RxSight.Article d’analyse • Dec 12
RxSight, Inc.'s (NASDAQ:RXST) 28% Price Boost Is Out Of Tune With Revenues
Despite an already strong run, RxSight, Inc. ( NASDAQ:RXST ) shares have been powering on, with a gain of 28% in the...Mise à jour du récit • Nov 28
RXST: Future Performance Will Hinge On Sustaining Outperformance Amid Lawsuit Uncertainty
Analysts have increased their price target for RxSight by $2 to $10, citing stronger than expected quarterly revenue performance and a favorable outlook for future estimates. Analyst Commentary Analysts have shared insights following the latest quarterly results for RxSight, highlighting both the optimistic outlook and areas of caution as the company navigates its growth trajectory.Mise à jour du récit • Nov 14
RXST: Future Performance Will Depend On Sustained Revenue Execution And Demand Consistency
Analysts have increased their price target for RxSight to $9.67 from $8.89, citing strong quarterly revenue performance well above expectations and expressing confidence in future revenue estimates. Analyst Commentary Following RxSight's latest quarterly results, analysts have highlighted several factors influencing their revised outlook for the company’s valuation and future performance.Article d’analyse • Oct 11
Lacklustre Performance Is Driving RxSight, Inc.'s (NASDAQ:RXST) 25% Price Drop
RxSight, Inc. ( NASDAQ:RXST ) shares have had a horrible month, losing 25% after a relatively good period beforehand...Seeking Alpha • Sep 22
The Bottom Fishing Club - RxSight: A Ski-Jump Reversal Pattern?
Summary RxSight may be outlining a 'ski-jump' technical pattern, suggesting the potential for a sharp short-term rebound. RXST holds $227 million in cash against $31 million in total liabilities, limiting downside risk with $379 million in equity market cap. The company’s cash runway is estimated at 5-10 years, with manageable annual cash burn of $20-30 million. A technical rally with short covering could yield gains of +50 to +100% in the near term, although a long-term bottom is not guaranteed on RXST stock. Read the full article on Seeking AlphaMise à jour du récit • Aug 10
Entry Into European And Asian Markets Will Unlock New Opportunities
RxSight’s consensus price target has been significantly reduced to $8.89 as analysts cite ongoing quarterly misses, slower customer adoption, plateauing utilization rates, and uncertainty around commercial strategy execution. Analyst Commentary Multiple bearish analysts cite consecutive quarterly misses and lowered guidance as primary concerns impacting RxSight's outlook.Article d’analyse • Aug 07
Investors Don't See Light At End Of RxSight, Inc.'s (NASDAQ:RXST) Tunnel And Push Stock Down 39%
RxSight, Inc. ( NASDAQ:RXST ) shareholders that were waiting for something to happen have been dealt a blow with a 39...Article d’analyse • Jul 19
Time To Worry? Analysts Just Downgraded Their RxSight, Inc. (NASDAQ:RXST) Outlook
Market forces rained on the parade of RxSight, Inc. ( NASDAQ:RXST ) shareholders today, when the analysts downgraded...Article d’analyse • Jun 18
The Price Is Right For RxSight, Inc. (NASDAQ:RXST)
When you see that almost half of the companies in the Medical Equipment industry in the United States have...Nouveau récit • May 08
South Korea And UK Approvals Will Expand Market Adoption
International expansion and regulatory approvals are poised to significantly boost revenue by entering new markets and enhancing clinical support.Article d’analyse • Apr 04
RxSight (NASDAQ:RXST) Is In A Strong Position To Grow Its Business
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Article d’analyse • Mar 08
RxSight, Inc. (NASDAQ:RXST) Shares Slammed 27% But Getting In Cheap Might Be Difficult Regardless
To the annoyance of some shareholders, RxSight, Inc. ( NASDAQ:RXST ) shares are down a considerable 27% in the last...Article d’analyse • Feb 28
RxSight, Inc. (NASDAQ:RXST) Just Reported, And Analysts Assigned A US$44.80 Price Target
Shareholders might have noticed that RxSight, Inc. ( NASDAQ:RXST ) filed its full-year result this time last week. The...Article d’analyse • Dec 06
The Price Is Right For RxSight, Inc. (NASDAQ:RXST)
You may think that with a price-to-sales (or "P/S") ratio of 13.3x RxSight, Inc. ( NASDAQ:RXST ) is a stock to avoid...Seeking Alpha • Nov 29
RxSight's Momentum In The Large Cataract Surgery Market Merits A Close Eye
Summary RxSight's light adjustable lenses [LAL] continue to gain traction in the $6 billion-plus cataract surgical market. In their Q3 earnings report, RxSight announced that 24,554 LALs were sold in Q3, representing an 80% YoY increase in volume compared to the same period last year. The company's healthy balance sheet supports continued efforts in driving adoption within the U.S. market, while also maintaining the necessary R&D investments to remain innovative in the long run. Due to solid financials and momentum in the large cataract surgery market, RXST is a "buy," but allocate accordingly and be aware of the risks. Read the full article on Seeking AlphaArticle d’analyse • Sep 04
We Think RxSight (NASDAQ:RXST) Can Easily Afford To Drive Business Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Seeking Alpha • Aug 13
Investing In The Future Of Cataract Surgery: The RxSight Advantage
Summary RxSight, Inc. is transforming cataract surgery with the Light Adjustable Lens system, offering postoperative customization for superior vision outcomes. The global cataract devices market is rapidly expanding, with RxSight well-positioned to capitalize on the growing demand for premium IOLs. Impressive financial performance in Q2 2024, with significant revenue growth, gross profit margin improvement, and raised full-year revenue guidance. The stock has 50% upside based on DCF valuation. Read the full article on Seeking AlphaArticle d’analyse • Aug 03
With A 27% Price Drop For RxSight, Inc. (NASDAQ:RXST) You'll Still Get What You Pay For
Unfortunately for some shareholders, the RxSight, Inc. ( NASDAQ:RXST ) share price has dived 27% in the last thirty...Article d’analyse • Jul 12
Why RxSight, Inc. (NASDAQ:RXST) Could Be Worth Watching
RxSight, Inc. ( NASDAQ:RXST ), is not the largest company out there, but it saw significant share price movement during...Seeking Alpha • Jul 10
RxSight: Great Business Model, Stretched Valuations
Summary Today, we revisit RxSight, Inc., whose stock has nearly quintupled since the end of 2022. The company has a solid business model and loss estimates have come down substantially since we last looked in October of last year. That said, the stock trades north of 15 times forward revenues and RxSight likely doesn't reach profitability until FY2027. Can the stock continue to head higher given that backdrop? An updated analysis follows below. Read the full article on Seeking AlphaArticle d’analyse • Jun 20
A Look At The Intrinsic Value Of RxSight, Inc. (NASDAQ:RXST)
Key Insights The projected fair value for RxSight is US$58.23 based on 2 Stage Free Cash Flow to Equity RxSight's...Article d’analyse • May 09
RxSight, Inc. (NASDAQ:RXST) Analysts Are Pretty Bullish On The Stock After Recent Results
RxSight, Inc. ( NASDAQ:RXST ) just released its latest quarterly results and things are looking bullish. Revenues beat...Article d’analyse • May 05
RxSight (NASDAQ:RXST) Is In A Strong Position To Grow Its Business
Just because a business does not make any money, does not mean that the stock will go down. For example, RxSight...Seeking Alpha • May 01
RxSight: Promising Technology, Uncertain Profitability - A Hold Recommendation
Summary RxSight offers a revolutionary adjustable IOL technology with superior outcomes and reduced side effects compared to traditional IOLs. The company's "razor-and-blade" business model, with the LAL and LDD, provides precise post-surgical vision adjustments. Despite impressive revenue growth, RxSight remains unprofitable, leading to a "Hold" recommendation due to high valuation and ongoing cash burn. Read the full article on Seeking AlphaArticle d’analyse • Apr 16
Why We're Not Concerned About RxSight, Inc.'s (NASDAQ:RXST) Share Price
With a price-to-sales (or "P/S") ratio of 22.1x RxSight, Inc. ( NASDAQ:RXST ) may be sending very bearish signals at...Article d’analyse • Mar 24
Is It Time To Consider Buying RxSight, Inc. (NASDAQ:RXST)?
While RxSight, Inc. ( NASDAQ:RXST ) might not have the largest market cap around , it saw a significant share price...Seeking Alpha • Jan 16
RxSight Stock: Time To Refocus Following Eye Watering Rally
Summary RxSight reported preliminary Q4 results, capping off a record year for growth where sales climbed by approximately 82%. The company is capturing strong demand for its adjustable intraocular lens technology for cataract and lens replacement surgery. Recognizing a positive outlook, we expect the stock to face renewed volatility against high expectations that may be difficult to surpass. Read the full article on Seeking AlphaArticle d’analyse • Jan 09
RxSight, Inc. (NASDAQ:RXST) Stocks Shoot Up 30% But Its P/S Still Looks Reasonable
Despite an already strong run, RxSight, Inc. ( NASDAQ:RXST ) shares have been powering on, with a gain of 30% in the...Article d’analyse • Dec 21
We Think RxSight (NASDAQ:RXST) Can Afford To Drive Business Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, RxSight...Rendement pour les actionnaires
| RXST | US Medical Equipment | US Marché | |
|---|---|---|---|
| 7D | 2.3% | 1.8% | 1.2% |
| 1Y | -62.0% | -17.9% | 28.7% |
Rendement vs Industrie: RXST a sous-performé le secteur US Medical Equipment qui a rapporté -17.9 % au cours de l'année écoulée.
Rendement vs marché: RXST a sous-performé le marché US qui a rapporté 28.7 % au cours de l'année écoulée.
Volatilité des prix
| RXST volatility | |
|---|---|
| RXST Average Weekly Movement | 8.9% |
| Medical Equipment Industry Average Movement | 8.8% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.1% |
Cours de l'action stable: RXST n'a pas connu de volatilité de prix significative au cours des 3 derniers mois par rapport au marché US.
Volatilité au fil du temps: La volatilité hebdomadaire de RXST ( 9% ) est restée stable au cours de l'année écoulée.
À propos de l'entreprise
| Fondée | Salariés | PDG | Site web |
|---|---|---|---|
| 1997 | 461 | Ron Kurtz | rxsight.com |
RxSight, Inc. est une société de technologie médicale à vocation commerciale qui se consacre à la recherche et au développement, à la fabrication et à la vente de lentilles intraoculaires ajustables à la lumière (LAL) utilisées dans la chirurgie de la cataracte aux États-Unis. Elle propose le système RxSight qui permet aux médecins de personnaliser et d'améliorer l'acuité visuelle des patients après une opération de la cataracte. Le système RxSight de la société comprend la lentille ajustable à la lumière (LAL) RxSight, une lentille intraoculaire composée d'un matériau photosensible qui change de forme en réponse à des modèles spécifiques d'ultraviolets, qui peut être ajustée pour améliorer l'acuité visuelle non corrigée ; et le dispositif d'administration de la lumière RxSight, un dispositif de traitement de la lumière en cabinet qui administre de la lumière UV selon un modèle programmé pour modifier la LAL en fonction de la correction visuelle nécessaire pour obtenir la vision souhaitée après une chirurgie de la cataracte.
RxSight, Inc. Résumé des fondamentaux
| RXST statistiques fondamentales | |
|---|---|
| Capitalisation boursière | US$251.90m |
| Bénéfices(TTM) | -US$46.64m |
| Recettes(TTM) | US$127.48m |
2.0x
Ratio P/S-5.4x
Ratio P/ELe site RXST est-il surévalué ?
Voir Juste valeur et analyse de l'évaluationBénéfices et recettes
| RXST compte de résultat (TTM) | |
|---|---|
| Recettes | US$127.48m |
| Coût des recettes | US$29.30m |
| Marge brute | US$98.18m |
| Autres dépenses | US$144.82m |
| Les revenus | -US$46.64m |
Derniers bénéfices déclarés
Mar 31, 2026
Prochaine date de publication des résultats
s/o
| Résultat par action (EPS) | -1.13 |
| Marge brute | 77.02% |
| Marge bénéficiaire nette | -36.59% |
| Ratio dettes/capitaux propres | 0% |
Quelles ont été les performances à long terme de RXST?
Voir les performances historiques et les comparaisonsAnalyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/05/26 19:02 |
| Cours de l'action en fin de journée | 2026/05/22 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
RxSight, Inc. est couverte par 15 analystes. 9 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Travis Steed | BofA Global Research |
| Michael Gorman | BTIG |
| Xuyang Li | Jefferies LLC |